Market Place
Sourcing Support
Takeda plots $900M restructuring plan as profits plummet
10 May 2024 //
FIERCE PHARMA
MSN`s Generic Lisdexamfetamine Dimesylate Receives Approval in the U.S.
02 Feb 2024 //
FDA
Takeda treads water despite loss of exclusivity on Vyvanse
01 Feb 2024 //
FIERCE PHARMA
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
06 Sep 2023 //
BUSINESSWIRE
Mallinckrodt Receives FDA Approval for Lisdexamfetamine Dimesylate to ADHD
31 Aug 2023 //
PR NEWSWIRE
Amid shortage, FDA clears several generics of Takeda`s Vyvanse
31 Aug 2023 //
FIERCE PHARMA
Takeda focuses on Qdenga as it braces for Vyvanse generics
27 Jul 2023 //
FIERCE PHARMA
As Adderall shortages persist, Takeda`s rival Vyvanse is now in short supply
22 Jun 2023 //
FIERCE PHARMA
Sun`s Generic Lisdexamfetamine Dimesylate Receives Approval in the U.S.
14 Jun 2023 //
FDA
Takeda expects patent expirations to weigh on earnings
13 May 2023 //
FIERCE PHARMA
Teva`s Generic Lisdexamfetamine Dimesylate Receives Approval in the U.S.
28 Nov 2022 //
FDA
Amneal`s Generic Lisdexamfetamine Dimesylate Receives Approval in the U.S.
18 Aug 2022 //
FDA
Actavis`s Generic Lisdexamfetamine Dimesylate Receives Approval in the U.S.
12 Aug 2022 //
FDA
Takeda boots Vyvanse out of its pipeline while another is delayed by war
12 May 2022 //
ENDPTS
Noramco Announces Submission of DMF for Lisdexamfetamine Dimesylate
03 Dec 2021 //
PRESS RELEASE
FDA Consults on Abuse-Deterrent CNS Stimulants
20 Sep 2019 //
RAPS
Health Canada Issues Recall of Shire Pharma Canada ULC Vyvanse Capsule
14 Aug 2019 //
HEALTH CANADA
Shire`s ADHD Candidate`s NDA Accepted by FDA
20 Jan 2017 //
NASDAQ
Harvoni, Lantus top Medicare, Medicaid drug spend as U.S. total hits $457B
15 Nov 2016 //
FIERCE PHARMA
Shire Updates Vyvanse US labeling to Include New Longer-term Efficacy Data
18 Oct 2016 //
PHARMABIZ
With weight-control peers flailing, Shire keeps growing Vyvanse
11 May 2016 //
FIERCE PHARMA
Shire Submits NDA to FDA for new formulation of Vyvanse CII as chewable tablets
15 Apr 2016 //
CPHI ONLINE
With Baxalta in hand, Shire`s not looking to buy. But sell? Maybe
11 Feb 2016 //
FIERCE PHARMA
Shire victorious in US Vyvanse patent battle
25 Sep 2015 //
PHARMA TIMES
Seven new medicines approved for NHS Scotland
07 Sep 2015 //
PHARMATIMES
First stimulant for ADHD in adults gets UK launch
26 Aug 2015 //
PHARMATIMES
Vyvanse set to steal ADHD share in back-to-school meds rush
19 Aug 2015 //
FIERCE PHARMA MARKETING
Workers Seeking Productivity in a Pill Are Abusing A.D.H.D. Drugs
17 Apr 2015 //
THE NEW YORK TIMES
Health Canada issues “stronger, clearer” warnings about suicide risks linked to ADHD drugs
03 Apr 2015 //
THE STAR
ADHD Drugs May Increase Risk Of Suicidal Thoughts And Behaviours In Some People; Benefits Still Outweigh Risks
01 Apr 2015 //
HEALTHY CANADIANS
Shire`s Vyvanse Brand Team Draws Fire for Aggressive Binge-Eating Push
26 Feb 2015 //
FIERCE PHARMA MARKETING
Binge Eating Added to List of Uses for Shire Drug by FDA
31 Jan 2015 //
BLOOMBERG
Supreme Court Pitches Patent Fight Over Shire`s Lialda After Teva Ruling
26 Jan 2015 //
FIERCE PHARMA
Shire Announces Positive Response from European DCP for Elvanse Adult in Adults with ADHD
23 Jan 2015 //
PHARMABIZ
Positive Response from European Decentralised Procedure for Elvanse Adult
22 Jan 2015 //
SHIRE PLC
Study Vyvanse Effective Option for Treating Binge Eating
14 Jan 2015 //
MED PAGE TODAY
